The BCR-ABL chimeric tyrosine kinase activates a number of downstream pathways that drive the pathogenesis of CML as well as other tumor types including a subset of acute lymphoblastic leukemia, acute myelogenous leukemia, and mixed-phenotype acute leukemias [3, 4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.